Article Text
Abstract
In this article, I examine children's reported experiences with stimulant drug treatments for attention deficit hyperactivity disorder in light of bioethical arguments about the potential threats of psychotropic drugs to authenticity and moral agency. Drawing on a study that involved over 150 families in the USA and the UK, I show that children are able to report threats to authenticity, but that the majority of children are not concerned with such threats. On balance, children report that stimulants improve their capacity for moral agency, and they associate this capacity with an ability to meet normative expectations. I argue that although under certain conditions stimulant drug treatment may increase the risk of a threat to authenticity, there are ways to minimise this risk and to maximise the benefits of stimulant drug treatment. Medical professionals in particular should help children to flourish with stimulant drug treatments, in good and in bad conditions.
- Children
- Neuroethics
- Psychiatry
- Psychopharmacology
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode
Statistics from Altmetric.com
Linked Articles
- Commentary
- Response
- Commentary
- Commentary
- The concise argument
Other content recommended for you
- Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results of the German Health Interview and Examination Survey (KiGGS)
- Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional study
- Assent as an ethical imperative in the treatment of ADHD
- Stimulant drugs for severe hyperactivity in childhood
- What place for ▼lisdexamfetamine in children and adolescents with ADHD?
- Service use in children aged 6–8 years with attention deficit hyperactivity disorder
- Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy
- Childhood attention-deficit/hyperactivity disorder
- Stimulant medication to treat attention-deficit/hyperactivity disorder
- Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial